Physician profile
Sandra Giron
NPI 1568430189
$803.84
in general payments reported to CMS, 2019-2025
17 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $28.07 · 2022: $29.09 · 2023: $69.04 · 2024: $77.73 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $300.00 | 2019 | |
| Hologic Sales and Service, LLC | $77.73 | 2024 | Aptima |
| Abbvie INC. | $68.28 | 2019-2025 | |
| Davol INC. | $44.95 | 2019 | |
| Exeltis, USA INC. | $43.58 | 2020-2023 | Slynd |
| Corcept Therapeutics | $42.90 | 2025 | Korlym |
| Ucb, INC. | $35.06 | 2025 | Bimzelx |
| Merck Sharp & Dohme LLC | $30.85 | 2019-2025 | Verquvo |
| Lupin INC. | $29.95 | 2019 | |
| Meditrina | $20.09 | 2023 | |
| Astellas Pharma US INC | $18.65 | 2023 | Veozah |
| Neurocrine Biosciences, INC. | $18.05 | 2025 | |
| Medtronic, INC. | $17.21 | 2025 | Minimed 780g |
| Novo Nordisk INC | $15.74 | 2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $15.00 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $14.11 | 2022 | |
| Pfizer INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Giron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.